A phase I/II clinical trial at the NIH Clinical Center will test the effectiveness of a vaccine against cancers linked to the human papillomavirus (HPV). The vaccine will be tested alone and in combination with a checkpoint inhibitor called M7824. The phase I portion of the trial is currently recruiting between 12 and 18 people with advanced HPV-related cancer. They will be treated over a…